Volumetric Biotechnologies specializes in bioprinting vascularized human tissues using proprietary photoinitiators and polyethylene glycol diacrylate materials. This technology addresses the need for functional tissue constructs in regenerative medicine and drug testing, enhancing the development of complex biological systems.

Anduril provides an autonomous operations platform that fuses data from drones, radar, lidar, satellite and other sensors into a real‑time situational awareness picture. Its edge AI and computer‑vision models detect, classify and track objects autonomously, delivering secure analytics to command interfaces for rapid decision‑making. The solution includes modular autonomous vehicles and a scalable command‑and‑control dashboard, enabling defense agencies to deploy advanced surveillance and reconnaissance capabilities with lower lifecycle costs.

Arctoris utilizes its automated laboratory platform, Ulysses™, to enhance drug discovery by improving data quality and experimental precision across various biological disciplines. The company addresses the inefficiencies in traditional R&D processes, enabling faster progression from target validation to candidate selection for biotech and pharmaceutical partners.

Aviron Interactive offers a gamified rowing machine that utilizes game psychology and design to enhance user engagement and motivation during workouts. The platform provides a variety of efficient, expert-designed fitness programs that combine strength, endurance, and cardio training, addressing the common issue of workout monotony.

Bolt provides a one-click checkout solution that connects e-commerce platforms to a network of over 80 million shoppers, enabling instant recognition of returning customers and seamless transactions. This technology addresses the high rate of cart abandonment by streamlining the purchasing process, thereby increasing conversion rates and boosting revenue for online retailers.

Vaxxinity develops and advances novel vaccine candidates, including a COVID-19 booster, utilizing a proprietary platform technology. Their vaccine candidates aim to provide long-lasting immunity that is effective against emerging variants without requiring a frozen cold chain. The company focuses on creating cost-effective and well-tolerated prophylactic solutions for infectious diseases.

Deciduous Therapeutics develops immune modulatory therapies that activate the body's natural immune mechanisms to eliminate senescent cells, which contribute to age-related diseases. By targeting these dysfunctional cells, the company aims to improve health span and mitigate the effects of inflammation and tissue remodeling associated with aging.

Deep Longevity employs artificial intelligence to analyze biomarkers of aging, enabling accurate evaluations of biological age. This technology provides essential insights into the aging process, facilitating personalized health interventions and advancements in longevity research.

This company accelerates small molecule drug discovery by integrating molecular physics simulations with AI-driven computational methods. They offer an intuitive, no-code AI assistant, Balto, for accessible drug discovery workflows including data retrieval, molecular profiling, and ligand docking. Additionally, they provide code-based API access for advanced users needing large-scale docking, free energy calculations, and molecular analysis.

The startup develops regenerative medicines that target the molecular mechanisms of aging by identifying blood factors that regulate biological repair and regeneration. Their approach aims to prevent and treat age-related diseases by reversing the damage caused by aging at a cellular level.

Encellin has developed a thin-film cell encapsulation device for Encapsulated Cell Replacement Therapy (EnCRT), enabling enclosed cells to function as therapeutic factories within the body. This technology addresses the issue of cell loss and dysfunction in endocrine disorders, particularly in type 1 diabetes, by providing a minimally invasive implant that delivers sustained therapeutic effects.

Framework designs modular consumer electronics that prioritize repairability and upgradeability, allowing users to easily replace components and customize their devices. This approach addresses the issue of electronic waste by extending product lifespans and minimizing environmental impact.

Gordian provides an in vivo drug discovery platform that uses aged animal “Patient Avatars”—models that naturally develop age‑related diseases—to screen pooled libraries of hundreds of therapeutic candidates in a process called Mosaic Screening. By integrating single‑cell sequencing, functional genomics, and AI‑driven analytics, the platform delivers quantitative efficacy data and prioritizes targets and candidates, helping pharma, biotech, and academic researchers improve the success rate of therapies for complex age‑related indications.

Insilico Medicine utilizes a generative AI platform to streamline drug discovery and development for cancer and age-related diseases, significantly reducing the time and cost associated with bringing new medications to market. The platform integrates multi-omics data analysis and machine learning to identify novel drug targets and predict clinical trial outcomes, enhancing the efficiency of pharmaceutical research.

This startup utilizes renewable agricultural practices and precision farming technology to produce food sustainably, addressing the urgent issue of global climate change. By optimizing resource use and minimizing carbon emissions in food production, the company aims to enhance food security while reducing environmental impact.

The startup offers a social discovery platform that utilizes algorithms to match users with similar interests for in-person gatherings in small groups. This approach addresses the challenge of fostering meaningful offline connections by facilitating shared experiences and community engagement.

Loki Therapeutics develops a next-generation platform for tumor-specific drug delivery. This technology focuses on enhancing therapeutic efficacy by targeting cancer cells with precision. The company is advancing novel treatments through its proprietary delivery mechanism.

Multiomic Health develops precision medicines for diseases derived from metabolic syndrome by integrating multi-omics data with longitudinal clinical phenotyping. The company uses AI-enabled data science to identify distinct molecular disease drivers within patient subpopulations. This approach enables the origination of therapeutic R&D programs with corresponding patient-stratifying companion diagnostics for higher clinical trial success rates.

Nanome provides a collaborative XR platform that integrates AI-assisted tools for drug discovery, enabling scientists to visualize and manipulate molecular structures in a shared virtual environment. This technology enhances decision-making and accelerates research by facilitating real-time analysis and communication among global teams.

The startup has developed a nanomedical platform that utilizes targeted nanoparticles to selectively remove disease-causing molecules from the bloodstream within minutes. This technology provides a new treatment option for major diseases, enhancing patient safety and efficacy compared to traditional methods.

Playco develops instant play games designed for mass multiplayer engagement across various platforms. The company focuses on creating accessible social gaming experiences that do not require additional application downloads. Their core technology supports fast, robust connections for millions of concurrent users.

Revel Pharmaceuticals develops therapies that target the excess accumulation of toxic proteins and metabolites, aiming to repair age-related damage and complications from chronic diseases such as osteoarthritis and diabetes. By addressing the root causes of aging and chronic illness, their solutions offer a pathway to reverse disease progression and improve patient outcomes.

Sampling Human focuses on integrating single-cell precision into health-related applications. The company aims to provide foundational biological insights derived from cellular analysis. This work supports more informed decision-making across various health domains.

This startup develops single-cell analysis tools utilizing printed droplet microfluidics for picoliter-scale manipulations through fluorescence-activated microfluidic droplet sorting. Their technology enables precise study of infectious cancer diseases, providing critical insights for clinical and research applications.